-
1 week ago | 
nature.com | Alanna J. Church |Heinz-Josef Lenz |Heather Hampel
Germline sequencing should be integrated with somatic testing of cancers to provide a comprehensive genetic assessment of disease.
-
1 month ago | 
nature.com | Dongshi Chen |Haibo Qiu |Heinz-Josef Lenz |Zhendong Jin |Jian Yu
AbstractOxysterol-binding proteins (OSBPs), lipid transfer proteins functioning at intracellular membrane contact sites, are recently found to be dysregulated in cancer and promote cancer cell survival. However, their role as potential targets in cancer therapy remains largely unexplored.
-
2 months ago | 
onclive.com | Heinz-Josef Lenz
Heinz-Josef Lenz, MD, a professor of medicine and cancer biology, and the J.
-
Feb 27, 2025 | 00057-1?rss=yes&sz=64)
cell.com | Hui-Yan Luo |Yun-Xin Lu |Kohei Shitara |Heinz-Josef Lenz |Rui-hua Xu
Get full text accessLog in, subscribe or purchase for full access. References1. Bray, F. ∙ Laversanne, M. ∙ Sung, H. ... Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countriesCA Cancer J. Clin. 2024; 74:229-2632. Sun, D. ∙ Gao, W. ∙ Hu, H. ... Why 90% of clinical drug development fails and how to improve it? Acta Pharm. Sin. B. 2022; 12:3049-30623. Wang, F. ∙ Ruan, D.-Y. ∙ Xu, R.-H.
-
Feb 6, 2025 | 
onclive.com | Heinz-Josef Lenz
CommentaryPodcastFebruary 6, 2025Author(s):Fact checked by:,Dr Lenz discusses the prevalence of RAS mutations in PDAC, the importance of biomarker testing, and treatment advances for patients with this disease. Welcome to OncLive On Air®! I’m your host today, Jax DiEugenio. OncLive On Air is a podcast from OncLive®, which provides oncology professionals with the resources and information they need to provide the best patient care.
-
Feb 6, 2025 | 
onclive.com | Heinz-Josef Lenz
First results of nivolumab plus ipilimumab vs nivolumab monotherapy for microsatellite instability high/ mismatch repair-deficient metastatic colorectal cancer from CheckMate 8HW Dr. Heinz-Josef Lenz presents first results from the CheckMate 8HW trial, demonstrating that nivolumab plus ipilimumab significantly improves progression-free survival and overall response rates compared to nivolumab monotherapy in patients with microsatellite instability-high/mismatch repair-deficient metastatic...
-
Sep 3, 2024 | 
nature.com | Jennifer R Ribeiro |Heinz-Josef Lenz |Scott Kopetz
AbstractWe developed a whole transcriptome sequencing (WTS)-based Consensus Molecular Subtypes (CMS) classifier using FFPE tissue and investigated its prognostic and predictive utility in a large clinico-genomic database of CRC patients (n = 24,939). The classifier was trained against the original CMS datasets using an SVM model and validated in an independent blinded TCGA dataset (88.0% accuracy).
-
Aug 21, 2024 | 
nature.com | Midhun Malla |Timothy Samec |Heinz-Josef Lenz |Emil Lou |Sanjay Goel |Dane C. Olevian
AbstractThe expression of the protein Mesothelin (MSLN) is highly variable in several malignancies, including colorectal cancer (CRC), and high levels are associated with aggressive clinicopathological features and worse patient survival. Colorectal cancer is both a common and deadly cancer; being the third most common in incidence and second most common cause of cancer-related death.
-
Jun 21, 2024 | 
onclive.com | Heinz-Josef Lenz
Heinz-Josef Lenz, MD, FACP, associate director, Clinical Research, chair, Gastrointestinal Oncology Program, codirector, Colorectal Center, University of Southern California Norris Comprehensive Cancer Center; professor, Department of Medicine, Department of Preventive Medicine, Division of Oncology, Keck School of Medicine, discusses findings from an expanded efficacy analysis from the phase 3 CheckMate 8HW trial (NCT04008030).
-
Jun 13, 2024 | 
nature.com | Andrea Bullock |Benjamin L. Schlechter |Marwan Fakih |Joseph E. Grossman |Rachel E. Sanborn |Bruno Bockorny | +3 more
AbstractMicrosatellite stable metastatic colorectal cancer (MSS mCRC; mismatch repair proficient) has previously responded poorly to immune checkpoint blockade. Botensilimab (BOT) is an Fc-enhanced multifunctional anti-cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) antibody designed to expand therapy to cold/poorly immunogenic solid tumors, such as MSS mCRC. BOT with or without balstilimab (BAL; anti-PD-1 antibody) is being evaluated in an ongoing expanded phase 1 study.
